Effect of Telbivudine,Entecavir Treatment on Patients with Hepatitis B Liver Cirrhosis in Compensatory Stage

Objective:To evaluate the clinic efficacy of Telbivudine and Entecavir treatment for Chronic Hepatitis B with liver fibrosis.Method: 120 cases of Chronic Hepatitis B with liver fibrosis were randomly divided into two groups,based on conventional liver protection therapy,the observation group(n=60)treated with 600 mg of Telbivudine a day,the control group(n=60)treated with 0.5 mg of Entecavir a day.The course of treatment lasted 48 weeks. Result:(1)At week 48,The liver function and hepatic fibrosis index had been improved between two groups(P 0.01).(2)In observation group and control group,the HBV DNA negative rate was 86.7% and 88.3% respectively,which the HBeAg/antiHBe seroconversion rate of the observation group HBeAg/HBeAb was significantly higher than that of control group(35% vs.11.7%, P 0.01).(3)There was no severely adverse reaction occurred during treatment stage. Conclusion:Telbivudine could suppress HBV replication,improve liver function and HBeAg/antiHBe seroconversion rate,and it’s has good safety.